Difference between revisions of "Autoimmune cytopenia"

From HemOnc.org - A Hematology Oncology Wiki
Jump to navigation Jump to search
m (Text replacement - "www.ncbi.nlm.nih.gov/pubmed" to "pubmed.ncbi.nlm.nih.gov")
Line 42: Line 42:
  
 
===References===
 
===References===
# Willis F, Marsh JC, Bevan DH, Killick SB, Lucas G, Griffiths R, Ouwehand W, Hale G, Waldmann H, Gordon-Smith EC. The effect of treatment with Campath-1H in patients with autoimmune cytopenias. Br J Haematol. 2001 Sep;114(4):891-8. [https://onlinelibrary.wiley.com/doi/10.1046/j.1365-2141.2001.03039.x/full link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/11564082 PubMed]
+
# Willis F, Marsh JC, Bevan DH, Killick SB, Lucas G, Griffiths R, Ouwehand W, Hale G, Waldmann H, Gordon-Smith EC. The effect of treatment with Campath-1H in patients with autoimmune cytopenias. Br J Haematol. 2001 Sep;114(4):891-8. [https://onlinelibrary.wiley.com/doi/10.1046/j.1365-2141.2001.03039.x/full link to original article] '''contains verified protocol''' [https://pubmed.ncbi.nlm.nih.gov/11564082 PubMed]
  
 
==Sirolimus monotherapy {{#subobject:35516b|Regimen=1}}==
 
==Sirolimus monotherapy {{#subobject:35516b|Regimen=1}}==
Line 68: Line 68:
  
 
===References===
 
===References===
# Bride KL, Vincent T, Smith-Whitley K, Lambert MP, Bleesing JJ, Seif AE, Manno CS, Casper J, Grupp SA, Teachey DT. Sirolimus is effective in relapsed/refractory autoimmune cytopenias: results of a prospective multi-institutional trial. Blood. 2016 Jan 7;127(1):17-28. Epub 2015 Oct 26. [http://www.bloodjournal.org/content/127/1/17.long link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4705607/ link to PMC article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/26504182 PubMed]
+
# Bride KL, Vincent T, Smith-Whitley K, Lambert MP, Bleesing JJ, Seif AE, Manno CS, Casper J, Grupp SA, Teachey DT. Sirolimus is effective in relapsed/refractory autoimmune cytopenias: results of a prospective multi-institutional trial. Blood. 2016 Jan 7;127(1):17-28. Epub 2015 Oct 26. [http://www.bloodjournal.org/content/127/1/17.long link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4705607/ link to PMC article] '''contains protocol''' [https://pubmed.ncbi.nlm.nih.gov/26504182 PubMed]
  
 
[[Category:Autoimmune cytopenia regimens]]
 
[[Category:Autoimmune cytopenia regimens]]

Revision as of 02:12, 25 February 2020

Section editor
Tillman Benjamin-2.jpg
Benjamin Tillman, MD
Vanderbilt University
Nashville, TN
2 regimens on this page
2 variants on this page


This is an umbrella category that includes Felty's syndrome (autoimmune neutropenia), autoimmune thrombocytopenia (ITP), autoimmune hemolytic anemia (AIHA), and Evan's syndrome (AIHA & ITP). Please see the respective page(s) for disease-specific therapies. This page includes regimens that were used more broadly.

Relapsed or refractory

Alemtuzumab monotherapy

back to top

Regimen

Study Evidence Efficacy
Willis et al. 2001 Phase II ORR: 71%

Immunosuppressive therapy

  • Alemtuzumab (Campath) as follows:
    • Test dose: 1 mg IV over 60 minutes once
    • Days 1 to 10: 10 mg IV over 4 hours once per day

10-day course

References

  1. Willis F, Marsh JC, Bevan DH, Killick SB, Lucas G, Griffiths R, Ouwehand W, Hale G, Waldmann H, Gordon-Smith EC. The effect of treatment with Campath-1H in patients with autoimmune cytopenias. Br J Haematol. 2001 Sep;114(4):891-8. link to original article contains verified protocol PubMed

Sirolimus monotherapy

back to top

Regimen

Study Evidence Efficacy
Bride et al. 2015 Phase II Durable CR observed in patients with ALPS

Immunosuppressive therapy

6-month course, extended for those with a favorable response

References

  1. Bride KL, Vincent T, Smith-Whitley K, Lambert MP, Bleesing JJ, Seif AE, Manno CS, Casper J, Grupp SA, Teachey DT. Sirolimus is effective in relapsed/refractory autoimmune cytopenias: results of a prospective multi-institutional trial. Blood. 2016 Jan 7;127(1):17-28. Epub 2015 Oct 26. link to original article link to PMC article contains protocol PubMed